分组1 - Avita Medical Inc. (RCEL) shares have increased by 17.9% over the past four weeks, closing at $5.39, with a mean price target of $7 indicating a potential upside of 29.9% [1] - The mean estimate consists of four short-term price targets with a standard deviation of $3.03, where the lowest estimate is $3.50 (a 35.1% decline) and the highest is $10.00 (an 85.5% increase) [2] - Analysts show strong agreement on RCEL's ability to report better earnings than previously predicted, which supports the view of potential upside [4] 分组2 - The Zacks Consensus Estimate for RCEL's current year earnings has increased by 12.2% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RCEL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, the implied direction of price movement appears to be a useful guide [14]

David said gross margin was 82.1% for 2025 and 81% in the fourth quarter. He attributed the year’s results to inventory reserves booked during the year that he said would not recur, as well as a continuing product-mix impact tied to revenue-sharing arrangements for newer products.Cary said the company grew about 11% in 2025 despite disruptions, and expects 12% to 19% growth in 2026. Finance leader David added that Avita has historically grown at a compound annual growth rate of about 32% , and said manageme ...

Core Viewpoint - Avita Medical Inc. (RCEL) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, which subsequently affects stock prices [4]. Business Outlook - The upgrade in Zacks Rank for Avita Medical suggests an improvement in the company's underlying business, which could lead to an appreciation in stock value as investors respond positively to this trend [5][10]. - For the fiscal year ending December 2026, Avita Medical is expected to earn -$0.97 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 12.2% over the past three months, indicating a positive revision trend [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - The upgrade of Avita Medical to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Company Overview - AVITA Medical is currently undergoing a leadership transition with Cary Vance serving as Interim CEO and David O'Toole as CFO [2][3] - The company is focused on improving its business predictability and credibility following a challenging period in 2025 [3] Business Goals - The primary objective for the fourth quarter was to gain a better understanding of the business to enable accurate forecasting, which was successfully achieved [4] - Looking ahead to 2026, the company aims to grow in a disciplined and methodical manner [4]

AVITA Medical (NasdaqCM:RCEL) Update / briefing February 18, 2026 05:00 PM ET Company ParticipantsBen Atkins - VP of Investor Relations and Corporate CommunicationsCary Vance - Interim CEODavid O'Toole - CFOCary VanceUnderstanding, trying to understand our business, wanting to become more, predictable, forecastable, credible, to, to understand how we might remove some of the noise and distraction as well around our, our covenants. And, the goal over the fourth quarter was not only to start, understanding ou ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

As we said last quarter, predictable reimbursement not only for our products, but also for the clinicians who use them, is what allows our strong clinical and real-world health economic data to translate into routine standard use of ReCell. With that clarity in place, we are now seeing early signs of utilization beginning to normalize as accounts reengage. Ultimately, growth in this business is driven less by adding new hospital accounts and more by increasing adoption, utilization, and repeated use of our ...

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $17.6 million and full-year revenue of approximately $71.6 million, representing about 11% growth over 2024 [5][11] - Full-year gross margin was 82.1%, down from 85.8% in 2024, due to inventory reserves and product mix changes [12] - Fourth quarter gross margin was 81.2%, compared to 87.6% for the same period last year [13] Business Line Data and Key Metrics Changes - The focus for 2025 was on resolving reimbursement uncertainty for the RECELL product, with six of the seven Medicare Administrative Contractors publishing payment rates for RECELL procedures [6] - Approximately 90% of revenue comes from about 200 burn and trauma centers, with a shift towards organic monthly usage patterns rather than bulk ordering [6][7] Market Data and Key Metrics Changes - The company is taking a disciplined distributor-led approach to expand its footprint in select international markets, focusing on establishing familiarity and operational readiness [9] - Initial clinical use of RECELL GO in European markets has begun, with a focus on responding to urgent needs in the burn community [9] Company Strategy and Development Direction - The strategy is centered around a single integrated platform consisting of RECELL, Cohealyx, and PermeaDerm, aimed at increasing adoption and utilization among clinicians [7] - The company expects full-year revenue for 2026 to be between $80 million and $85 million, reflecting growth of approximately 12% to 19% over 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of establishing a disciplined operating model and improving visibility into cash use, which are expected to support consistent execution in 2026 [4][10] - The company aims to maintain disciplined control of operating costs while supporting revenue growth with a stable and scalable cost structure [17] Other Important Information - The company refinanced its debt through a new credit facility, which is designed to reduce covenant risk and support execution rather than constrain it [16] - The fourth quarter marked the third consecutive quarter of improvement in net cash use, declining from $10.1 million in Q2 to $5.1 million in Q4 [15] Q&A Session Summary Question: Guidance on revenue covenants and growth pace - Management clarified that the $15.4 million revenue covenant is not a guidance figure and indicated that they expect growth to be progressive from Q4 to Q1 and throughout the year [20][25] Question: Reimbursement dynamics affecting 2025 - Management confirmed that they are engaged with all seven MACs and are optimistic about the seventh MAC publishing payment rates soon, with no concerns about disruptions [30][31] Question: Customer experience with Cohealyx and PermeaDerm - Management discussed the process of working with champions in accounts to facilitate the adoption of Cohealyx and PermeaDerm, noting early positive experiences [37][38] Question: Drivers of growth for 2026 guidance - Management indicated that growth will be driven by increased utilization within existing accounts and contributions from all three product lines, including RECELL, Cohealyx, and PermeaDerm [49]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $17.6 million and full-year revenue of approximately $71.6 million, representing about 11% growth over 2024 [5][11] - Full year gross margin was 82.1%, down from 85.8% in 2024, reflecting inventory reserves and product mix changes [12] - Fourth quarter gross margin was 81.2%, compared to 87.6% for the same period last year [13] Business Line Data and Key Metrics Changes - Approximately 90% of revenue comes from about 200 burn and trauma centers, with a focus on increasing adoption and utilization of products like RECELL, Cohealyx, and PermeaDerm [6][7] - The Cohealyx I post-market study is fully enrolled, and the PermeaDerm I study is nearing full enrollment, with data expected later in 2026 [8] Market Data and Key Metrics Changes - Six of the seven Medicare administrative contractors have published payment rates for RECELL procedures, which is expected to restore confidence among clinicians [6] - The company is taking a disciplined distributor-led approach in select international markets, focusing on establishing operational readiness [9] Company Strategy and Development Direction - The company aims to drive disciplined execution, refine commercial focus, and position for growth in 2026, with a strategy centered around an integrated platform of products [4][10] - The company expects full year revenue of $80 million to $85 million in 2026, representing growth of approximately 12% to 19% over 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of predictable reimbursement for products and the need for increased adoption and utilization by clinicians [6][18] - The company is focused on maintaining disciplined control of operating costs and supporting revenue growth with a stable cost structure [17] Other Important Information - The company refinanced its debt through a new credit facility, which provides more flexibility and reduces covenant risk [15][16] - The fourth quarter marked the third consecutive quarter of improvement in net cash use, declining from $10.1 million in Q2 to $5.1 million in Q4 [15] Q&A Session Summary Question: Guidance on revenue covenants and growth pace - Management clarified that the $15.4 million covenant is not a guidance figure and that they expect growth to continue from Q4 into Q1 and throughout the year [20][21] Question: Reimbursement dynamics affecting 2025 - Management confirmed engagement with all seven MACs and expressed optimism about the seventh MAC publishing payment rates soon [30][31] Question: Customer experience with Cohealyx and PermeaDerm - Management discussed the process of working with champions in accounts to facilitate the adoption of Cohealyx and PermeaDerm, noting early positive experiences [37][38] Question: Drivers of growth for 2026 guidance - Management indicated that growth will come from increased utilization within existing accounts and contributions from Cohealyx and PermeaDerm [49]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $17.6 million and full-year revenue of approximately $71.6 million, representing about 11% growth over 2024 [5][12] - Full year gross margin was 82.1%, down from 85.8% in 2024, reflecting inventory reserves and product mix changes [12] - Fourth quarter gross margin was 81.2%, compared to 87.6% for the same period last year [13] - Total operating expenses in the fourth quarter were $24.7 million, down 5% year-over-year, primarily due to lower sales and marketing expenses [14] Business Line Data and Key Metrics Changes - The company focused on increasing adoption and utilization of its products, with approximately 90% of revenue coming from about 200 burn and trauma centers [6][8] - The Cohealyx I post-market study is fully enrolled, and the PermeaDerm I study is nearing full enrollment, with data expected later in 2026 [9] Market Data and Key Metrics Changes - Six of the seven Medicare administrative contractors have published payment rates for RECELL procedures, which has begun to restore confidence for clinicians [6] - The company is taking a disciplined distributor-led approach to build its footprint in select international markets [10] Company Strategy and Development Direction - The company aims to drive disciplined execution, refine commercial focus, and position itself for growth in 2026 [4] - The strategy is built around a single integrated platform of RECELL, Cohealyx, and PermeaDerm, used repeatedly by the same clinicians [8] - The company expects full year revenue of $80 million-$85 million in 2026, representing growth of approximately 12%-19% over 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of predictable reimbursement for products and clinicians to drive routine use of RECELL [6] - The company is focused on establishing the right operating cadence and executing fundamentals well to ensure consistent progress [8] - Management expressed confidence in the normalization of RECELL utilization and the expansion of portfolio use within core accounts [11] Other Important Information - The company refinanced its debt through a new credit facility, which provides more flexibility and reduces covenant risk [15][16] - The fourth quarter marked the third consecutive quarter of improvement in net cash use, declining to $5.1 million [15] Q&A Session Summary Question: Guidance on revenue growth pace - Management clarified that the $15.4 million revenue covenant is not a guidance figure and that they expect progressive growth from Q4 to Q1 and throughout the year [22][26] Question: Reimbursement dynamics affecting 2025 - Management confirmed that they are engaged with all seven MACs and are hopeful for the seventh MAC to publish payment rates soon [30][31] Question: Customer experience with Cohealyx and PermeaDerm - Management indicated that champions in accounts are helping to push Cohealyx and PermeaDerm through the VAC process, with early signs of uptake [37][38] Question: Drivers of growth for 2026 guidance - Management expects growth from all three product lines, primarily driven by increased utilization within existing accounts [48]